Home
About
Program
Registration
Sponsors
Contact

Home
About
Program
Registration
Sponsors
Contact

Speakers

Keynote Speakers

Dr Martina Benešová-Schäfer

German Cancer Research Center
Germany

Dr Martina Benešová-Schäfer

German Cancer Research Center

Martina Benešová-Schäfer leads the Junior Research Group Translational Radiotheranostics at the German Cancer Research Center (DKFZ) in Heidelberg, Germany. She studied Nuclear Chemistry and Clinical Toxicology at Charles University in the Czech Republic and earned her PhD in Radiopharmaceutical Chemistry from DKFZ. Her postdoctoral training was conducted at the Paul Scherrer Institute (PSI) in Villigen and at ETH Zürich in Switzerland.

Her interdisciplinary research focuses on the physicochemical and biological properties of alpha particle-emitting radionuclides. She specializes in the development of targeted radioligands for diagnostic, prognostic, therapeutic, and theranostic applications. Martina Benešová-Schäfer has made contributions to the development of PSMA-targeting radioligands, including PSMA-617, PSMA-1007, and PSMA-ALB- 56. Driven by a strong commitment to personalized medicine, her work aims to expand treatment options and improve outcomes for patients with limited therapeutic alternatives.

Prof Alberto Briganti

Vita-Salute San Raffaele University
Italy

Prof Alberto Briganti

Prof Alberto Briganti MD, PhD
Professor of Urology
Vita-Salute San Raffaele University

Alberto Briganti is Full Professor of Urology at Vita-Salute University San Raffaele, Milan, Italy where he also acts as deputy director of the Urological Research Institute (URI) and responsible for the Robotic Program in Urology. He is the Chair of the Prostate Cancer Clinical and Research program at Vita-Salute University, San Raffaele Hospital. He earned his MD in 2002 at Vita-Salute University where he also pursued residency.

He completed uro-oncological fellowship at the Cancer Prognostics and Health Outcomes Unit, University of Montreal in 2006. In 2016 he obtained his Ph.D in Clinical and Experimental Biotechnology in Urology. He is a member of the Scientific Congress Office of the EAU and current Editor in Chief of European Urology (2024 IF: 25.2). He is also a member of the Scientific Committee of the European Multidisciplinary Meeting on Urological Cancer (EMUC). He is a fellow of the European Board of Urology (EBU) and a Faculty member of the European School of Urology (ESU).

He is the 2016 EAU Crystal Matula Award winner. He has published more than 1,500 peer-reviewed publications. His main area of interests include urological oncology.

Prof Louise Emmett

St Vincent's Hospital Sydney
Australia

Prof Louise Emmett

Prof Louise Emmett
Nuclear Medicine Physician
St Vincent's Hospital Sydney

Prof Louise Emmett is the Director of Theranostics and Nuclear medicine at St Vincent’s Hospital Sydney, Australia with a specialty interest in the imaging and therapy of prostate Cancer. She undertook her medical undergraduate training in Auckland, New Zealand, prior to completing her specialty training in Nuclear Medicine in Sydney, and a post specialty Nuclear Cardiology fellowship in Toronto, Canada. She commenced work in Nuclear medicine and PET at St Vincent’s Hospital, Sydney in 2012, initiating radio-pharmacy production of multiple new imaging and therapy peptides on the St Vincent’s campus for clinical and research evaluation. She is principal investigator in multiple phase I-II trials including the PRIMARY trial (PSMA + MRI in prostate diagnosis), PRIMARY2 (randomised phase III imaging trial), LuPIN trial (Phase I/II trial of Lu PSMA+ Idronoxil), ENZAp( phase II randomised trial of enza vs enza + Lu PSMA), in addition to running multiple phase I imaging trials in new theranostic agents.

Dr Brian Gonzalez

Moffitt Cancer Center
USA

Dr Brian Gonzalez

Brian Gonzalez, PhD is Associate Center Director for Research Career Development and Associate Member in the departments of Health Outcomes & Behavior and Genitourinary Oncology at Moffitt Cancer Center.

He is an expert in examining patient-reported outcomes (PROs) among patients with prostate cancer. He also led development of the first PRO measure designed for use with patients receiving radionuclide therapy for prostate cancer. His research focuses on improving quality of life in cancer patients and survivors. He seeks to identify novel risk factors for worsening quality of life and develop interventions to improve quality of life in cancer patients and survivors.

Prof Andrei Iagaru

Stanford
USA

Prof Andrei Iagaru

Dr. Iagaru is a Professor of Radiology - Nuclear Medicine and the Chief of the Division of Nuclear Medicine and Molecular Imaging at Stanford University Medical Center. He completed medical school at Carol Davila University of Medicine, Bucharest, Romania, and an internship at Drexel University College of Medicine, Graduate Hospital, in the Department of Medicine in Philadelphia. He began his residency at the University of Southern California (USC) Keck School of Medicine, Los Angeles, in the Division of Nuclear Medicine. Dr. Iagaru finished his residency and completed a PET/CT fellowship at Stanford University's School of Medicine in the Division of Nuclear Medicine. His research interests include PET/MRI and PET/CT for early cancer detection; clinical translation of novel PET radiopharmaceuticals; peptide-based diagnostic imaging and therapy; targeted radionuclide therapy.

Since joining the faculty at Stanford in 2007, Dr. Iagaru has received several awards including the Society of Nuclear Medicine (SNM) 2009 Image of the Year Award; AuntMinnie 2016 Best Radiology Image, American College of Nuclear Medicine (ACNM) Mid-Winter Conference 2010 Best Essay Award; 2009, 2014 and 2015 Western Regional SNM Scientist Award; 2011 SNM Nuclear Oncology Council Young Investigator Award; the 2020 Sanjiv Sam Gambhir Distinguished Scientist Award, Western Regional SNM; the 2022 Sanjiv Sam Gambhir Trailblazer Award, SNMMI; the 2022 Distinguished Investigator Award, The Academy for Radiology & Biomedical Imaging Research and the 2023 Presidential Award, SNMMI. Dr. Iagaru published more than 240 papers in peer-reviewed journals, as well as 9 book chapters and 1 book.

Prof Tobias Maurer

Martini-Klinik University Medical Centre Hamburg-Eppendorf
Germany

Prof Tobias Maurer

Prof. Dr. med. Tobias Maurer, FEBU 26.10.1975

Faculty
Martini-Klinik and Department of Urology University of Hamburg-Eppendorf, Germany

Martini-Str. 52 Gebäude Ost 46, 20246 Hamburg, Germany
Phone: +49 (0)40 7410-51300
Email: t.maurer@uke.de
Web: https://www.martini-klinik.de/klinik/team/faculty/prof-maurer

Educational and Professional Experience
Since 2018 – Faculty at the Martini-Klinik Prostate Cancer Center, University of Hamburg-Eppendorf, Hamburg, Germany
2017–2018 – Senior Attending Urologist, Department of Urology, Technical University of Munich (TUM), Klinikum rechts der Isar, Germany
2011–2016 – Attending Urologist, Department of Urology, TUM, Klinikum rechts der Isar
2009–2011 – Urologist, Department of Urology, TUM
1997–2009 – Medical training and residency at the Technical University of Munich

Professional Memberships
European Association of Urology (EAU)
European Society of Urological Imaging (ESUI), Associate Member
German Urology Association (DGU)
Vereinigung Norddeutscher Urologen e.V. (VNU)

Clinical and Scientific Focus
Prostate cancer (imaging, surgery, medical therapy)
PSMA-PET imaging and PSMA-radioguided surgery

Honors and Awards
More than 30 national and international awards and stipends, selected:
2017 – Award for Research and Innovation in Urooncology, German Urological Association (DGU), for PSMA-radioguided surgery
2015 – EAU-AUA Scientific Exchange Programme Stipend (USA)
2011 – Award from the German Society of Immunotherapy (DGFIT)
2000–2002 – Stipend of the German Research Foundation (DFG)

Reviewer Assignments
Reviewer for >40 peer-reviewed journals
Advisory Board, Nature Reviews Urology
Reviewer for grant applications including DFG, NWO, KWF, Wilhelm-Sander-Stiftung, King’s Health Partners R&D Fund, Cancer Research UK

Third-party Funding
Total > €1,000,000, including:
DFG (SFB 824, project B11, co-investigator)
EU FP7 (sub-investigator)
DFG (Graduate College 333 for doctoral thesis)

Clinical Study Experience
Co-Investigator on >30 clinical studies, Principal Investigator on 4, including 3 IITs:
• ProSTone (NCT04271579)
• BioPoP (NCT04324983)
• PräVAC (EUDAMED: CIV-12-07-008204; 2013–2018)

Publication List
285 publications (cumulative IF >1400); h-Index: 62
Selected publications:
• Knipper S et al. Eur Urol. 2022 Jun 16. [PMID: 35718637]
• de Barros HA et al. Eur Urol. 2022 Mar 23. [PMID: 35339318]
• Amiel T et al. J Urol. 2021 Jun. [PMID: 33535796]
• Knipper S et al. Eur Urol. 2020 Dec. [PMID: 33317857]
• Maurer T et al. J Nucl Med. 2020 Jan. [PMID: 31732677]
• Horn T et al. Eur Urol. 2019 Oct. [PMID: 30987843]
• van Leeuwen FWB et al. Nat Rev Urol. 2019 Jan. [PMID: 30644446]
• Maurer T et al. Eur Urol. 2018 Apr. [PMID: 29625755]
• Maurer T et al. J Urol. 2016 May. [PMID: 26682756]
• Maurer T et al. Nat Rev Urol. 2016 Apr. [PMID: 26902337]

A/Prof Alicia Morgans

Dana Farber Cancer Institute
USA

A/Prof Alicia Morgans

Dr. Morgans is an Associate Professor of Medicine at Harvard Medical School, a Genitourinary Medical Oncologist and the Director of the Survivorship Program at Dana-Farber Cancer Institute. As a clinician and investigator, she has expertise in clinical trials and patient-reported outcome measures, as well as incorporating patient preferences and beliefs into clinical decision making. Her research has investigated complications of systemic therapy for prostate cancer survivors, including the study of skeletal, cardiovascular, diabetic, and cognitive complications, and her work has been funded by grants from the Prostate Cancer Foundation , the National Comprehensive Cancer Network, and the Department of Defense. She leads multiple therapeutic and quality of life focused clinical trials for prostate cancer patients, and has participated in the advanced and localized prostate cancer treatment guidelines committees of the American Urologic Association, and the cardio-oncology committee of American Heart Association.

Local Speakers

A/Prof Narjess Ayati

Nuclear Medicine Specialist
St Vincent's Hospital Sydney

Prof Arun Azad

Medical Oncologist
Peter MacCallum Cancer Centre

Prof Dale Bailey

Medical Physicist
University of Sydney

Prof Dale Bailey

PhD FACPSEM FIPEM MRCP (Lond.) CSci (UK)
Medical Physicist
University of Sydney

Dale Bailey is a nuclear medicine physicist who has had a career-long focus on quantification in emission tomographic imaging using both SPECT & PET. Dale is currently the Principal Medical Physics Specialist in the Department of Nuclear Medicine at Royal North Shore Hospital, Sydney and is a professor in the Faculty of Medicine & Health at the University of Sydney. Dale has published in excess of 230 peer-reviewed articles and mentored over 40 post-graduate students predominantly on the theme of developing accurate in vivo measurements in nuclear medicine imaging as well as editing four textbooks. Dale is a Past-President of the Australian & New Zealand Society of Nuclear Medicine (ANZSNM) from 2016-2018.

Dr James Buteau

Nuclear Medicine Physician
Peter MacCallum Cancer Centre

Ms Brittany Emmerson

Nuclear Medicine Technologist
Peter MacCallum Cancer Centre

Dr Renu Eapen

Urologist
Peter MacCallum Cancer Centre

Prof Ros Francis

Medical Physicist
University of Queensland

A/Prof Luc Furic

Head of Translational Prostate Cancer Research
Peter MacCallum Cancer Centre

A/Prof Mohammad Haskali

Chief Radiopharmaceutical Scientist
Peter MacCallum Cancer Centre

Prof Michael Hofman

Chair of the ProsTIC Preceptorship 2024 and Director of Prostate Cancer Theranostics and Imaging Centre of Excellence, Nuclear Medicine Physician

Dr Price Jackson

Medical Physicist
Peter MacCallum Cancer Centre

Dr Louise Kostos

Medical Oncologist
Peter MacCallum Cancer Centre

Dr Sidney Levy

Nuclear Medicine Specialist
Peter MacCallum Cancer Centre

A/Prof Daniel Moon

Urologist
Peter MacCallum Cancer Centre

A/Prof Daniel Moon

Urologist
Peter MacCallum Cancer Centre

A/Prof Daniel Moon is a Urologist with subspecialty expertise in robotic prostate and renal surgery. He served as the inaugural Director of Robotic Surgery at Epworth Healthcare 2012-2017 and is an Honorary Clinical Associate Professor at The University of Melbourne. He has performed over 2500 robotic procedures, published the first Australian series of laparoscopic radical prostatectomy in 2008, performed the first Australian robotic cysto-prostatectomy in 2009, and established a robotic partial nephrectomy program at Peter MacCallum Cancer Centre, publishing the first Australian series of this procedure in 2014 and the largest Australian partial nephrectomy series in 2017. Amongst recent nuclear medicine research projects A/Prof Moon co-authored the PRIMARY trial and was one of the lead investigators for PRIMARY2.